Skip to content

Castle Biosciences

US · CSTL #3242 by market cap Listed 2019
32.86 -0.55 -1.63%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Valuation each multiple against its own 5-year range

P/B ratio 2.18 Expensive vs history 85th percentile
5-year average 1.67 · #12 of 41 in Diagnostics & Research
P/E ratio -44.46 Cheap vs history 32nd percentile
5-year average -30.57 · forward -43.01
P/S ratio 2.76 In line with history 45th percentile
5-year average 3.93 · forward 2.45 · #18 of 44 in Diagnostics & Research

Vs. peers Diagnostics & Research

Company Market cap P/E (TTM) P/B Div yield
Castle Biosciences (CSTL) 1.01B -43.24 2.12 0.00%
Thermo Fisher Scientific (TMO) 248.08B 35.31 4.53 0.27%
Danaher (DHR) 155.03B 36.12 2.89 0.69%
IDEXX Laboratories Inc (IDXX) 53.28B 45.57 28.50 0.00%
Agilent Technologies (A) 48.04B 33.61 6.52 0.59%
Waters (WAT) 43.29B 184.29 2.83 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★☆☆ Fair value34.68 Economic moatNone UncertaintyHigh

Trading 5.5% below Morningstar's fair value estimate.

Fair value

Castle Biosciences Inc receives a 3-star quantitative star rating, reflecting our opinion that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a minor 3% discount to our quantitative fair value estimate of $34.68 per share; however, caution is warranted due to this estimate's high uncertainty rating.

The company's solid growth bolsters our estimated valuation. Consistent revenue and earnings growth indicates a company's potential for increased market share and profitability. For example, the firm's revenue 3-year growth of 23.6% ranks in the top 20% compared with global peers. Robust trailing three-year revenue growth portends a favorable future trajectory, which contributes to our view that shares are cheap.

Alternatively, the company's lack of profitability is potentially concerning. Companies with low profitability are often less resilient in recessions and are likely to generate weaker future cash flows for shareholders. The firm's earnings yield of 1.0%, a core component of profitability, sits in the bottom 40% globally. The earnings generated by the company relative to its share price is concerning, which, despite our favorable price/fair value ratio, is a negative attribute.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. This outperformance bodes well for future returns in light of other contributors to our model.

Economic moat

With its quantitative economic moat rating of none, this business is unlikely to consistently outearn its cost of capital without structural protection from competition. However, its financial health score is strong, suggesting that the company should be well positioned to weather tough times.

By Quantitative Equity Report

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Castle Biosciences discussion 0 comments

Add a comment